Sangamo Therapeutics (NASDAQ:SGMO) Stock Rating Reaffirmed by HC Wainwright

Sangamo Therapeutics (NASDAQ:SGMO)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $5.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 293.70% from the stock’s current price.

Separately, StockNews.com assumed coverage on shares of Sangamo Therapeutics in a research report on Sunday, July 28th. They set a “sell” rating for the company. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $2.67.

Sangamo Therapeutics Stock Performance

Shares of NASDAQ SGMO traded up $0.36 during midday trading on Tuesday, reaching $1.27. The company’s stock had a trading volume of 54,668,260 shares, compared to its average volume of 6,280,023. The company has a market cap of $264.44 million, a P/E ratio of -0.92 and a beta of 1.23. Sangamo Therapeutics has a fifty-two week low of $0.29 and a fifty-two week high of $1.48. The business’s 50 day moving average price is $0.86 and its two-hundred day moving average price is $0.66.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.01). Sangamo Therapeutics had a negative net margin of 2,033.69% and a negative return on equity of 273.25%. The firm had revenue of $0.36 million during the quarter, compared to the consensus estimate of $11.40 million. Sell-side analysts forecast that Sangamo Therapeutics will post -0.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sangamo Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. State Board of Administration of Florida Retirement System lifted its stake in Sangamo Therapeutics by 61.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 23,650 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Sangamo Therapeutics during the second quarter worth $67,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Sangamo Therapeutics during the second quarter worth $89,000. Marshall Wace LLP lifted its stake in shares of Sangamo Therapeutics by 56.3% in the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock valued at $207,000 after acquiring an additional 207,476 shares during the last quarter. Finally, Vontobel Holding Ltd. boosted its holdings in shares of Sangamo Therapeutics by 412.3% during the 3rd quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company’s stock valued at $259,000 after acquiring an additional 241,440 shares in the last quarter. 56.93% of the stock is currently owned by institutional investors and hedge funds.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.